TG Therapeutics Quarterly Balance Sheet
NASDAQ: TGTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
TG Therapeutics financial position
As of Jun 30, 2026, TG Therapeutics reported total assets of $1.64 billion, up 133.4% from a year earlier against total liabilities of $1.04 billion. Shareholders' equity stood at $604.1 million, or 36.8% of assets. The company held $482.6 million in cash and equivalents against $745.4 million of debt, a net debt position of $262.8 million.
The current ratio (current assets divided by current liabilities) was 4.27, meaning short-term assets cover obligations due within a year. Debt-to-equity was 1.23.
Summary generated from market data by MetaCap's automated system. Methodology
TG Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 482.57M | 442.21M | 79.15M | 74.08M | 129.13M | 132.14M | 179.89M | 195.82M | 82.91M | 75.48M | 92.93M | 150.90M |
| Short-Term Investments | 69.67M | 72.22M | 62.82M | 57.50M | 122.74M | 144.10M | 131.11M | 145.22M | 134.34M | 134.31M | 124.58M | 78.26M |
| Receivables | 401.56M | 392.05M | 305.63M | 265.38M | 231.52M | 190.12M | 129.19M | 115.73M | 83.61M | 64.98M | 51.09M | 39.32M |
| Inventory | 147.97M | 129.03M | 125.59M | 146.95M | 155.20M | 157.76M | 110.46M | 84.67M | 81.24M | 77.72M | 39.82M | 33.55M |
| Total Current Assets | 1.15B | 1.09B | 630.76M | 599.76M | 663.96M | 644.51M | 566.36M | 574.07M | 389.15M | 360.58M | 317.94M | 319.11M |
| Property, Plant & Equipment | — | — | — | — | — | — | — | — | — | 66.00K | 95.00K | 133.00K |
| Goodwill | — | — | — | — | — | — | — | — | — | 799.00K | 799.00K | 799.00K |
| Long-Term Investments | 64.37M | 61.54M | 59.14M | 48.76M | 28.59M | 1.91M | 808.00K | 1.13M | 947.00K | 1.32M | 0 | 0 |
| Total Assets | 1.64B | 1.53B | 1.06B | 1.03B | 702.61M | 656.69M | 577.69M | 586.01M | 401.21M | 373.32M | 329.59M | 331.07M |
| Accounts Payable | 213.69M | 148.84M | 107.51M | 112.34M | 134.02M | 133.93M | 58.30M | 101.41M | 93.47M | 87.27M | 38.47M | 39.74M |
| Short-Term Debt | — | — | — | — | — | — | — | — | — | — | — | 0 |
| Total Current Liabilities | 268.49M | 187.11M | 153.76M | 156.81M | 171.89M | 160.21M | 90.68M | 125.11M | 108.66M | 99.68M | 53.72M | 57.68M |
| Long-Term Debt | 745.39M | 745.14M | 245.65M | 245.34M | 245.04M | 244.73M | 244.43M | 244.16M | 102.54M | 101.33M | 100.12M | 98.91M |
| Total Liabilities | 1.04B | 945.71M | 415.23M | 417.81M | 426.18M | 419.40M | 355.33M | 393.86M | 223.64M | 213.21M | 169.09M | 166.30M |
| Shareholders' Equity | 604.08M | 583.13M | 648.02M | 607.22M | 276.43M | 237.29M | 222.36M | 192.16M | 177.57M | 160.11M | 160.50M | 164.77M |
| Retained Earnings | -1.05B | -1.06B | -1.08B | -1.11B | -1.50B | -1.52B | -1.53B | -1.55B | -1.56B | -1.53B | -1.55B | -1.50B |
| Total Debt | 745.39M | 745.14M | 245.65M | 245.34M | 245.04M | 244.73M | 244.43M | 244.16M | 102.54M | 101.33M | 100.12M | 98.91M |
| Net Cash (Debt) | -193.14M | -230.71M | -103.67M | -113.76M | 6.83M | 31.51M | 66.57M | 96.88M | 114.72M | 108.46M | 117.39M | 130.25M |
| Shares Outstanding | 153.08M | 153.09M | 155.31M | 155.21M | 158.03M | 158.17M | 155.84M | 155.78M | 154.83M | 154.57M | 151.42M | 151.45M |
This table shows 12 quarterly periods of TG Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow TGTX's reporting calendar. What is a balance sheet?